File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Network meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs.
Title | Network meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs. |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Medcom Limited. The Journal's web site is located at http://www.hkcchk.com/journals.php#3 |
Citation | The 25th Annual Scientific Congress of the Hong Kong College of Cardiology, Hong Kong, 16-18 June 2017. In The Journal of the Hong Kong College of Cardiology, 2017, v. 25 n. 1, p. 18 How to Cite? |
Abstract | Purpose: Few randomised controlled trials directly compared the effect of new antidiabetic drugs on cardiovascular outcomes in patients with type 2 diabetes (T2D). We performed a network meta-analysis to assess the cardiovascular effects of these drugs.
Methods: We searched for randomised controlled trials that reported rates of major adverse cardiovascular events (MACE) and deaths in T2D patients with established cardiovascular risks, involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Data were analysed using frequentist approach and Bayesian framework in R. Results: Seven randomised controlled trials with altogether 62268 T2D patients were included for analysis. Compared to placebo, GLP-1 RAs and the SGLT-2 inhibitor reduced MACE (OR 0.89, 95%CI 0.82-0.97 and OR 0.85, 95%CI 0.73-0.99, respectively) and all-cause mortality (OR 0.89, 95%CI 0.80-0.99 and OR 0.67, 95%CI 0.55-0.81, respectively). The SGLT-2 inhibitor was more beneficial than GLP-1 RAs in reducing all-cause mortality (OR
0.76, 95%CI 0.61-0.94). DPP-4 inhibitors increased all-cause mortality when compared to GLP-1 RAs (OR 1.16, 95%CI 1.01-1.33) and the SGLT-2 inhibitor (OR 1.53, 95%CI 1.24-1.89).
Conclusions: GLP-1 RAs and the SGLT-2 inhibitor reduced the risk of MACE and all-cause mortality. DPP-4 inhibitors were inferior to these two drug classes in reducing cardiovascular events. The SGLT-2 inhibitor was the best in preventing deaths among the three antidiabetic drugs classes. |
Description | Free Paper Session |
Persistent Identifier | http://hdl.handle.net/10722/247878 |
ISSN | 2023 SCImago Journal Rankings: 0.115 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fei, Y | - |
dc.contributor.author | Tsoi, MF | - |
dc.contributor.author | Kumana, CR | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2017-10-18T08:34:06Z | - |
dc.date.available | 2017-10-18T08:34:06Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | The 25th Annual Scientific Congress of the Hong Kong College of Cardiology, Hong Kong, 16-18 June 2017. In The Journal of the Hong Kong College of Cardiology, 2017, v. 25 n. 1, p. 18 | - |
dc.identifier.issn | 1027-7811 | - |
dc.identifier.uri | http://hdl.handle.net/10722/247878 | - |
dc.description | Free Paper Session | - |
dc.description.abstract | Purpose: Few randomised controlled trials directly compared the effect of new antidiabetic drugs on cardiovascular outcomes in patients with type 2 diabetes (T2D). We performed a network meta-analysis to assess the cardiovascular effects of these drugs. Methods: We searched for randomised controlled trials that reported rates of major adverse cardiovascular events (MACE) and deaths in T2D patients with established cardiovascular risks, involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Data were analysed using frequentist approach and Bayesian framework in R. Results: Seven randomised controlled trials with altogether 62268 T2D patients were included for analysis. Compared to placebo, GLP-1 RAs and the SGLT-2 inhibitor reduced MACE (OR 0.89, 95%CI 0.82-0.97 and OR 0.85, 95%CI 0.73-0.99, respectively) and all-cause mortality (OR 0.89, 95%CI 0.80-0.99 and OR 0.67, 95%CI 0.55-0.81, respectively). The SGLT-2 inhibitor was more beneficial than GLP-1 RAs in reducing all-cause mortality (OR 0.76, 95%CI 0.61-0.94). DPP-4 inhibitors increased all-cause mortality when compared to GLP-1 RAs (OR 1.16, 95%CI 1.01-1.33) and the SGLT-2 inhibitor (OR 1.53, 95%CI 1.24-1.89). Conclusions: GLP-1 RAs and the SGLT-2 inhibitor reduced the risk of MACE and all-cause mortality. DPP-4 inhibitors were inferior to these two drug classes in reducing cardiovascular events. The SGLT-2 inhibitor was the best in preventing deaths among the three antidiabetic drugs classes. | - |
dc.language | eng | - |
dc.publisher | Medcom Limited. The Journal's web site is located at http://www.hkcchk.com/journals.php#3 | - |
dc.relation.ispartof | Journal of the Hong Kong College of Cardiology | - |
dc.title | Network meta-analysis of cardiovascular outcomes in randomised controlled trials of new antidiabetic drugs. | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Kumana, CR: hrmekcr@hku.hk | - |
dc.identifier.email | Cheung, TT: tcheungt@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, TT=rp01682 | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.hkuros | 282092 | - |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 18 | - |
dc.identifier.epage | 18 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 1027-7811 | - |